COGT — Cogent Biosciences, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1622229 ·
Last close
$27.85
Market Cap
$4.85B
52W High
$43.73
52W Low
$26.36
ADV30
2,242,779
Next earnings
2026-11-09

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -117,184,000 -111,426,000 832,142,000 217,461,000 315,884,000
Jun 2026 0 — -102,638,000 -96,405,000 834,546,000 181,172,000 302,158,000
Mar 2026 0 — -103,607,000 -97,352,000 903,006,000 241,208,000 295,313,000
Dec 2025 0 — -99,493,000 -102,492,000 937,607,000 312,012,000 301,236,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-307,545,000
Investing CF
$-499,992,000
Financing CF
$861,527,000
CapEx
$-1,695,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.27
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,382,177,000
Inventory
—
Receivables
—
ST Investments
$611,128,000
EBIT TTM
$-372,001,000
Pretax Income TTM
$-377,179,000
Interest Exp TTM
$5,178,000
Analysts
11

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -333,363,000 -328,937,000 937,607,000 301,236,000 636,371,000 -264,444,000
Dec 2024 0 -275,939,000 -255,859,000 327,898,000 71,612,000 256,286,000 -207,791,000
Dec 2023 0 -208,130,000 -192,410,000 313,437,000 55,635,000 257,802,000 -153,624,000
Dec 2022 0 -147,839,000 -140,241,000 300,810,000 45,075,000 255,735,000 -118,638,000

TTM Snapshot

Revenues TTM
$24,433,000
NetIncome TTM
$-377,179,000
OpCashFlow TTM
—
Assets (Latest)
$834,546,000
Forward EPS
$-1.27

Max Pain — expiry 2027-01-15

max pain strike: $30.00 · spot: $27.81 · call oi: 9,363 · put oi: 1,168
Expected Move to 2027-01-15: ±$6.88 (24.72%) — implied range $20.93 – $34.68 · ATM straddle on $28.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ERAS Erasca, Inc. $4.87B $13.89 —
DNTH Dianthus Therapeutics, Inc. /DE/ $4.90B $86.98 —
TVTX Travere Therapeutics, Inc. $4.91B $51.10 —
GIKLY Grifols SA $4.69B $5.55 —
PTCT PTC THERAPEUTICS, INC. $5.04B $60.36 —

News headlines (Yahoo Finance, 1h cache)

Cogent Biosciences (COGT) Stock Looks Fully Priced Against Its Asset Base
2026-11-18 02:17 · Yahoo
Cogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw Closer
2026-11-06 10:14 · Yahoo
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
2026-11-05 21:01 · Yahoo
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
2026-10-20 16:32 · Yahoo
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
2026-09-25 10:10 · Yahoo
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
2026-09-24 18:12 · Yahoo
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
2026-09-24 12:11 · Yahoo
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
2026-09-15 12:00 · Yahoo
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
2026-06-30 12:00 · Yahoo
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?
2026-06-22 14:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.